Hematology Frontier

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the hi

On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.

In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing on hot topics, comprehensively interpreting new advances in hematologic diseases, and helping you stay at the forefront of the disease field. Let's track the latest trends together, gain insights into research trends, and explore the boundless possibilities in the world of hematology! Stay tuned every month for the latest updates!

The "News Express" column serves as a bridge between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to swiftly capture industry trends, ignite innovative thinking, and broaden their professional perspectives. Hematology Frontier carefully selects the latest hematological research findings from top global journals. Each article is a brilliant spark of science and clinical practice, delivering the latest advancements in hematology directly to you. Let knowledge know no boundaries, and let exploration never cease. We invite you to follow the column and join global hematology experts on a journey of scientific discovery! This special issue compiles notable leukemia research from the past six months in Blood Reviews. We invite you to explore these highlights.

The "11th Sino-French Hematology Summit of the Chinese Medical Doctor Association," organized by the Chinese Medical Doctor Association, the Hematology Branch of the Chinese Medical Doctor Association, and the French Hematology Association, and hosted by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) and the National Clinical Research Center for Hematological Diseases—Peking University Hematology Institute, with the support of the French Bo Xiao Foundation under the French Fund General Assembly, is scheduled to be held in Tianjin from September 13 to 15, 2024. The conference theme focuses on "New Advances in the Treatment of Hematological Malignancies," delving into the latest clinical diagnosis and treatment progress, current hot topics, and core challenges in clinical practice related to the hematopoietic system. This conference sincerely invites authoritative experts in the field of hematology from both international and domestic circles to share their insights and experiences. It is planned to invite 150 hematologists from across the country to participate and exchange academic experiences. We warmly welcome clinicians on the front line of hematology to actively participate in the meeting and jointly promote progress in the field of hematological malignancy treatment.

The "News Express" column serves as a bridge between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to swiftly capture industry dynamics, ignite innovative thinking, and broaden their professional perspectives. Hematology Frontier carefully selects the latest hematological research findings from top global journals. Each article is a brilliant spark of science and clinical practice, delivering the latest advancements in hematology directly to you. Let knowledge know no boundaries, and let exploration never cease. We invite you to follow the column and join global hematology experts on a journey of scientific discovery! This issue features a review article from Pediatric Blood & Cancer on the role of Vinca alkaloids, a must-read.

The 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Jian Hou from Renji Hospital of Shanghai JiaoTong University School of Medicine, to share insights on the current status, challenges, and future treatment modes of multiple myeloma (MM).